PT-141 (Bremelanotide)Melanocortin PeptideSafety Rating 8/10
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Price Comparison
Compare vendors · per 10mg
| Vendor | Price | $ / mg | Updated | |
|---|---|---|---|---|
| Amino ClubBest $/mgCOA ✓ · 3P | $23.99 | $2.40 | May 14, 2026 | Buy → |
| Ascension PeptidesCOA ✓ · 3P | $25.00 | $2.50 | Apr 16, 2026 | Buy → |
| Puratek PeptidesCOA ✓ · 3P | $28.30 | $2.83 | May 19, 2026 | Buy → |
| Petratide ScienceCOA ✓ · 3P | $34.95 | $3.50 | May 14, 2026 | Buy → |
| Optimum FormulaCOA ✓ · 3P | $35.99 | $3.60 | May 14, 2026 | Buy → |
Overview
About PT-141
Mechanism of action
Melanocortin receptor agonist (MC3R, MC4R). Acts centrally in the hypothalamus to stimulate sexual arousal independent of the vascular system. Does not affect blood pressure like PDE5 inhibitors.
Safety profile
Nausea (most common), flushing, headache, transient blood pressure increase, spontaneous erections, hyperpigmentation with repeated use. · FDA-approved for HSDD; nausea common (40%); transient BP increase; limited to 1 dose/24hr
Storage
Stability & handling
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops PT-141 below your target.
Safety & Interactions
Contraindications & Drug Interactions
Research use only — not medical advice. Consult a licensed physician before using any peptide. Sources are cited where available.
Uncontrolled hypertension.
Known cardiovascular disease.
Transient BP increase (~6 mmHg SBP, ~3 mmHg DBP) lasting ~8 hours after each dose. Avoid in patients with CV risk factors.
Related pages
More on PT-141
Stack & Compare
Frequently Researched Together
Research
Studies & key findings
- FDA-approved (Vyleesi, 2019) for hypoactive sexual desire disorder (HSDD) in premenopausal women — the first centrally-acting pharmacological treatment for female sexual dysfunction.
- Two identical Phase 3 RCTs confirmed statistically and clinically significant increases in satisfying sexual events and decreases in distress scores vs placebo.